Citations

Clear

361 citation(s) found for "Bauer, M".

The Efficacy of a Multimodal Bedroom-Based ‘Smart’ Alarm System on Mitigating the Effects of Sleep Inertia
Campanella, Carolina , Byun, Kunjoon , Senerat, Araliya , Li, Linhao , Zhang, Rongpeng , Aristizabal, Sara , Porter, Paige , Bauer, Brent A. , Bauer, Brent A , Porter, Paige

Mayo Clinic

Clocks & Sleep | March 18, 2024 | Volume: 6 | Issue: 1 | Pages: 183-199

10.3390/clockssleep6010013 | PMID 38534801 Get It

Previous work has demonstrated the modest impact of environmental interventions that manipulate lighting, sound, or temperature on sleep inertia symptoms. The current study sought to expand on previous work and measure the impact of a multimodal intervention that collectively manipulated light, sound, and ambient temperature on sleep inertia. Participants slept in the lab for four nights and were awoken each morning by either a traditional alarm clock or the multimodal intervention. Feelings of sleep inertia were measured each morning through Psychomotor Vigilance Test (PVT) assessments and ratings of sleepiness and mood at five time-points. While there was little overall impact of the intervention, the participant’s chronotype and the length of the lighting exposure on intervention mornings both influenced sleep inertia symptoms. Moderate evening types who received a shorter lighting exposure (≤15 min) demonstrated more lapses relative to the control condition, whereas intermediate types exhibited a better response speed and fewer lapses. Conversely, moderate evening types who experienced a longer light exposure (>15 min) during the intervention exhibited fewer false alarms over time. The results suggest that the length of the environmental intervention may play a role in mitigating feelings of sleep inertia, particularly for groups who might exhibit stronger feelings of sleep inertia, including evening types.
Robotics in Massage: A Systematic Review
Yang, Juan , Lim, Kia Hui , Mohabbat, Arya B. , Fokken, Shawn C. , Johnson, Devan E., Calva, Jason J., Do, Alexander , Mueller, Michael , Chon, Tony Y. , Bauer, Brent A.

Mayo Clinic

Health Services Research and Managerial Epidemiology | February 20, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23333928241230948 | PMID 38379713 Get It

Background Over the past few years, a growing number of studies have explored massage robots. However, to date, a dedicated systematic review focused solely on robot-assisted massage has not been conducted. Objective To systematically identify and summarize evidence from studies concerning robot-assisted massage in healthcare settings. Methods An extensive literature search, involving electronic databases Ovid and Scopus, was conducted from the inception of the databases up to March 2023. This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, and relevant papers were chosen based on the predefined inclusion criteria. Given the substantial methodological diversity among the included studies, a qualitative analysis was conducted. Results Seventeen studies met the inclusion criteria, comprising 15 preliminary trials, one quasi-experimental study, and one randomized controlled trial. Approximately 29% of the studies focused on the application of robotic massage for patients, 24% targeted both healthy volunteers and patients, and the remaining 47% were preclinical trials assessing the effectiveness of robotic massage solely on healthy volunteers. Primary interventions included robotic massage for oral rehabilitation, scalp massage, low back massage, shoulder massage, and full-body massage. All studies provided evidence that robotic massage interventions can enhance health and well-being, indicating a promising future for the integration of robotics in the field of massage therapy. Conclusions In general, robotic massage interventions offer physical and mental health benefits. Robot-assisted massage may be integrated into care provision as an adjunct to enhance human well-being. Nonetheless, further research is needed to confirm these findings.
Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Somaiah, Neeta , Singh, Arun S. , Attia, Steven , Agulnik, Mark , Tap, William D. , Jones, Robin L. , Zou, Liangxing, Moynihan, Kevin, Lawrence, Julia, Wagner, Andrew J. , Jones, Robin L , Heinrich, Michael C. , Trent, Jonathan C. , Wilky, Breelyn A , Burgess, Melissa , Bauer, Sebastian , Serrano, César

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: TPS766-TPS766

10.1200/jco.2024.42.3_suppl.tps766 Get It

TPS766 Background: Imatinib is the worldwide standard for first-line therapy of advanced KIT-mutant GIST. However, secondary resistance mutations in the KIT ATP-binding domain (exons 13, 14), activation loop (exons 17, 18), or both develop and result in loss of imatinib-sensitivity. While no single tyrosine kinase inhibitor (TKI) inhibits all KIT mutations, the combination of bezuclastinib + sunitinib targets commonly occurring primary (exons 9, 11) and secondary (exons 13, 14, 17, and 18) KIT mutations. In a Phase 1/2 clinical study, pts with relapsed and/or refractory GIST and a median of 3 prior lines of therapy treated with bezuclastinib + sunitinib (n=15) experienced clinical benefit and an acceptable safety profile, warranting further evaluation in a randomized trial. Methods: Peak (NCT05208047) is a global, randomized, open-label, multi-part Phase 3 study evaluating the efficacy and safety of bezuclastinib + sunitinib versus sunitinib as second-line treatment in adult pts who were intolerant to imatinib or whose tumors had imatinib-resistance. The lead-in portion, to test a new formulation of bezuclastinib, (Part 1) has completed enrollment. Based upon PK and safety, a dose of bezuclastinib 600 mg QD + sunitinib 37.5 mg QD has been determined for Part 2 of the Peak study. Part 2 will enroll ~388 pts to be randomized (1:1) to bezuclastinib 600 mg QD + sunitinib 37.5 mg QD or sunitinib 37.5 mg QD alone. Key inclusion: >1 measurable lesion per modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1, Eastern Cooperative Oncology Group Performance Status 0-2, adequate organ function, and prior imatinib therapy (no other prior therapy). Key exclusion: PDGFR mutations or succinate dehydrogenase deficiency, clinically significant cardiac disease, and use of strong CYP3A4 inhibitors or inducers. The primary endpoint is progression-free survival (PFS) confirmed by blinded independent central review per mRECIST v1.1. Additional efficacy (including overall survival and objective response rate) and safety endpoints will be evaluated. Clinical trial information: NCT05208047 .
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
Jones, Robin L. , Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Davis, Erika, Achour, Haroun, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , investigators, on behalf of the INTRIGUE study, Jones, Robin L , Zalcberg, John , Blay, Jean‐Yves , George, Suzanne , Gelderblom, Hans , Mehren, Margaret von , Kang, Yoon‐Koo , Trent, Jonathan C. , Cesne, Axel Le , Bauer, Sebastian , Heinrich, Michael C. , investigators, on behalf of the INTRIGUE study

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 748-748

10.1200/jco.2024.42.3_suppl.748 Get It

748 Background: Ripretinib is a switch-control tyrosine kinase inhibitor approved for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with 3 or more kinase inhibitors, including imatinib. Sunitinib is approved for advanced GIST after imatinib failure. In the second interim analysis of overall survival (OS) from the phase 3 INTRIGUE study, the OS event rate was 41% in the all-patient (AP) intent-to-treat (ITT) population, and OS was similar between treatment arms in both the KIT exon 11 ITT and AP ITT populations. Here, we present the final OS and updated safety from INTRIGUE. Methods: INTRIGUE (NCT03673501) is an open-label, phase 3 study of adults with advanced GIST who had disease progression on or intolerance to imatinib. Randomization was 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 weeks on/2 weeks off) and was stratified by KIT mutational status and imatinib intolerance. OS was a key secondary endpoint (the primary endpoint of progression-free survival was reported previously); final OS analysis was prespecified to occur with ≥200 and ≥145 events in the AP ITT and KIT exon 11 ITT populations, respectively. Data cutoff was March 15, 2023. Results: Of 453 pts, 444 received treatment; 40 remain on treatment (ripretinib, 28/223 [13%]; sunitinib, 12/221 [5%]). Treatment discontinuation was due to progressive disease (PD) by independent radiologic review (56%), PD by investigator (11%), clinical PD (6%), withdrawal of consent (6%), and adverse events (AEs; 5%). Fewer pts discontinued treatment due to AEs with ripretinib vs sunitinib (3% vs 6%). There were 211 OS events (47%) in the AP ITT population and 151 OS events (46%) in the KIT exon 11 ITT population. OS was similar with ripretinib vs sunitinib in the 2 ITT populations (Table). Fewer pts had grade 3/4 treatment-emergent AEs with ripretinib vs sunitinib (43% vs 67%). Dose interruptions and reductions were lower with ripretinib vs sunitinib. Median treatment duration for ripretinib vs sunitinib was 7.9 vs 6.5 months. Conclusions: In the finalOS analysis from the INTRIGUE study, OS was similar between treatment arms. The safety profile remained consistent and more favorable for ripretinib vs sunitinib in pts with advanced GIST previously treated with imatinib. Clinical trial information: NCT03673501 . [Table: see text]
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer
Stinchcombe, Thomas E. , Wang, Xiaofei , Damman, Bryce , Mentlick, Jennifer, Landreneau, Rodney J., Wigle, Dennis A. , Conti, Massimo , Ashrafi, Ahmad S., Liberman, Moïshe , Mitchell, John D. , Keenan, Robert J. , Wigle, Dennis, Jones, David R , Conti, Massimo , de Perrot, Marc , Mitchell, John D , Jones, David R. , BAUER, THOMAS L , Miller, Daniel , Altorki, Nasser Khaled , Damman, Bryce

Mayo Clinic

Journal of Clinical Oncology | January 12, 2024 | Volume: 42 | Issue: 10 | Pages: 1110-1113

10.1200/jco.23.01306 | PMID 38215351 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Patients with early-stage non–small-cell lung cancer (NSCLC) who undergo curative surgical resection are at risk for developing second primary lung cancer (SPLC). Cancer and Leukemia Group B 140503 (Alliance) was a multicenter, international, randomized, phase III trial in patients with stage T1aN0 NSCLC (using the TNM staging system seventh edition) and demonstrated the noninferiority for disease-free survival between sublobar resection (SLR) and lobar resection (LR). After surgery, patients underwent computed tomography surveillance as defined by the protocol. The determination of a SPLC was done by the treating physician and recorded in the study database. We performed an analysis of the rate of SPLC (per patient per year) and the 5-year cumulative incidence in the study population and within the SLR and LR arms. Median follow-up was 7 years. The rate per patient per year in the study population, in the SLR arm, and in the LR arm was 3.4% (95% CI, 2.9 to 4.1), 3.8% (95% CI, 2.9 to 4.9), and 3.1% (95% CI, 2.4 to 4.1), respectively. The estimated 5-year cumulative incidence of SPLC in the study population, SLR arm, and LR arm was 15.9% (95% CI, 12.9 to 18.9), 17.2% (95% CI, 12.7 to 21.5), and 14.7% (95% CI, 10.6 to 18.7), respectively.
Abnormal REM Sleep Atonia Control in Patients With Chronic Post-Traumatic Stress Disorder (1607)
Feemster, John, Steele, Tyler, Palermo, Kyle P, Tao, Yumeng, Bauer, David A, Rivera, Sonia, Walters-Smith, Maxwell, Teigen, Luke, Timm, Paul, Gossard, Thomas , McCarter, Stuart J. , Louis, Erik K. St.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1607 Get It

Exploring the genetics of lithium response in bipolar disorders
Adli, Mazda , Akiyama, Kazufumi , Akula, Nirmala , Amare, Azmeraw T. , Ardau, Raffaella , Aubry, Jean‐Michel , Benabarre, Antonio , Bengesser, Susanne , Bhattacharjee, Abesh Kumar, Birner, Armin , Cearns, Micah , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Cruceanu, Cristiana , Dalkner, Nina , Zompo, Maria Del , Ferensztajn‐Rochowiak, Ewa , Forstner, Andreas J. , Frank, Josef , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Grof, Paul , Hsu, Yi‐Hsiang, Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , Maj, Mario , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , O’Donovan, Claire , Pfennig, Andrea , Pisanu, Claudia , Potash, James B. , Richard-Lepouriel, Hélène , Roberts, Gloria , Schalling, Martin , Schubert, Klaus Oliver , Schulte, Eva C. , Schweizer, Barbara , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Shimoda, Katzutaka, Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Streit, Fabian , Veeh, Julia, Witt, Stephanie H. , Zandi, Peter P. , Bauer, Michael , Witt, Stephanie H , Cichon, Sven , Amare, Azmeraw , Cruceanu, Cristiana , Schulte, Eva , Kittel-Schneider, Sarah , Lavebratt, Catharina , McCarthy, Michael , Pisanu, Claudia , Schubert, Klaus Oliver , Streit, Fabian , Mitjans, Marina , Herrera-Rivero, Marisol , Arias, Bárbara , Aubry, Jean‐Michel , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Chen, Hsi‐Chung , Colom, Francesc , Czerski, Piotr M. , Dalkner, Nina , Degenhardt, Franziska , DePaulo, J Raymond , Étain, Bruno , Falkai, Peter , Fullerton, Janice M. , Gallo, Carla , Garnham, Julie , Goes, Fernando , Grigoroiu‐Serbânescu, Maria , Hashimoto, Ryota , Hasler, Roland , Hauser, Joanna , Heilbronner, Urs , Herms, Stefan , Hoffmann, Per , Hou, Liping , Jamain, Stéphane , Jiménez, Esther , Kato, Tadafumi , Kelsoe, John R , Kuo, Po‐Hsiu , Kusumi, Ichiro , König, Barbara , Leboyer, Marion , Manchia, Mirko , Marie-Claire, Cynthia , Martinsson, Lina , McElroy, Susan L. , Millischer, Vincent , Monteleone, Palmiero , Nievergelt, Caroline M , Novák, Tomáš , Nöthen, Markus M. , Ozaki, Norio , Papiol, Sergi , Reif, Andreas , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Schofield, Peter R. , Squassina, Alessio , Stopková, Pavla , Tekola‐Ayele, Fasil , Thalamuthu, Anbupalam , Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Viswanath, Biju , Alda, Martin , McMahon, Francis J. , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Baune, Bernhard

Mayo Clinic

No container title available | December 2, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3677630/v1 | PMID 38077040 Get It

Abstract Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has been shown to have beneficial effects on disease-associated conditions, including sleep and cardiovascular disorders. However, the individual responses to Li treatment vary within and between diagnostic subtypes of BP (e.g. BP-I and BP-II) according to the clinical presentation. Moreover, long-term Li treatment has been linked to adverse side-effects that are a cause of concern and non-adherence, including the risk of developing chronic medical conditions such as thyroid and renal disease. In recent years, studies by the Consortium on Lithium Genetics (ConLiGen) have uncovered a number of genetic factors that contribute to the variability in Li treatment response in patients with BP. Here, we leveraged the ConLiGen cohort (N=2,064) to investigate the genetic basis of Li effects in BP. For this, we studied how Li response and linked genes associate with the psychiatric symptoms and polygenic load for medical comorbidities, placing particular emphasis on identifying differences between BP-I and BP-II. Results: We found that clinical response to Li treatment, measured with the Alda scale, was associated with a diminished burden of mania, depression, substance and alcohol abuse, psychosis and suicidal ideation in patients with BP-I and, in patients with BP-II, of depression only. Our genetic analyses showed that a stronger clinical response to Li was modestly related to lower polygenic load for diabetes and hypertension in BP-I but not BP-II. Moreover, our results suggested that a number of genes that have been previously linked to Li response variability in BP differentially relate to the psychiatric symptomatology, particularly to the numbers of manic and depressive episodes, and to the polygenic load for comorbid conditions, including diabetes, hypertension and hypothyroidism. Conclusions: Taken together, our findings suggest that the effects of Li on symptomatology and comorbidity in BP are partially modulated by common genetic factors, with differential effects between BP-I and BP-II.
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Petroni, Gina R. , Reilley, Matthew J. , Wolpin, Brian M. , Stucky, Chee‐Chee , Bekaii‐Saab, Tanios , Merchant, Nipun B. , Cardot‐Ruffino, Victoire , Pfaff, Kathleen L. , Dougan, Stephanie K. , Varadhachary, Gauri R., Slingluff, Craig L. , Rahma, Osama E. , Katz, Matthew H G , Reilley, Matthew J , Dougan, Stephanie K , Nowak, Jonathan A , Slingluff, Craig L , Bekaii-Saab, Tanios S , Katz, Matthew H. G. , Bauer, Todd W. , Elias, Rawad , Costa, Andressa Dias , Lenehan, Patrick J. , Rodig, Scott J , Nowak, Jonathan A.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | December 1, 2023 | Volume: 11 | Issue: 12 | Pages: e007586

10.1136/jitc-2023-007586 | PMID 38040420 Get It

Background Pancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall survival (OS). We hypothesized that adding programmed cell death protein 1 (PD-1) blockade to chemoradiotherapy would be well tolerated and increase TILs among patients with localized PDAC. Methods Patients were randomized 2:1 to Arm A (receiving pembrolizumab plus chemoradiotherapy (capecitabine and external beam radiation)) or Arm B (receiving chemoradiotherapy alone) before anticipated pancreatectomy. Primary endpoints were (1) incidence and severity of adverse events during neoadjuvant therapy and (2) density of TILs in resected tumor specimens. TIL density was assessed using multiplexed immunofluorescence histologic examination. Results Thirty-seven patients were randomized to Arms A (n=24) and B (n=13). Grade ≥3 adverse events related to neoadjuvant treatment were experienced by 9 (38%) and 4 (31%) patients in Arms A and B, respectively, with one patient experiencing dose-limiting toxicity in Arm A. Seventeen (71%) and 7 (54%) patients in Arms A and B, respectively, underwent pancreatectomy. Median CD8+ T-cell densities in Arms A and B were 67.4 (IQR: 39.2–141.8) and 37.9 (IQR: 22.9–173.4) cells/mm2, respectively. Arms showed no noticeable differences in density of CD8+Ki67+, CD4+, or CD4+FOXP3+ regulatory T cells; M1-like and M2-like macrophages; or granulocytes. Median OS durations were 27.8 (95% CI: 17.1 to NR) and 24.3 (95% CI: 12.6 to NR) months for Arms A and B, respectively. Conclusions Adding pembrolizumab to neoadjuvant chemoradiotherapy was safe. However, no convincing effect on CD8+ TILs was observed.
Orthopnea Secondary to Brachial Plexitis with Bilateral Diaphragmatic Paralysis
Labban, Mohamad El , Bauer, Philippe R.

Mayo Clinic

No container title available | November 29, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3635073/v1 Get It

Abstract Background: Diaphragmatic paralysis can present with orthopnea. We report a unique presentation of bilateral diaphragmatic paralysis, an uncommon diagnosis secondary to an unusual cause, brachial plexitis. This report thoroughly describes the patient’s presentation, workup, management, and outcome. It also reviews the literature on diaphragmatic paralysis and Parsonage-Turner syndrome. Case presentation: A 50-year-old male patient developed insidious orthopnea associated with left shoulder and neck pain over three months with no associated symptoms. On examination, marked dyspnea was observed when the patient was asked to lie down; breath sounds were present and symmetrical, and the neurological examination was normal. The chest radiograph showed an elevated right hemidiaphragm. Echocardiogram was normal. There was a 63% positional reduction in Forced Vital Capacity and maximal inspiratory and expiratory pressures on pulmonary function testing. The electromyogram was consistent with neuromuscular weakness involving both brachial plexus and diaphragmatic muscle (Parsonage and Turner syndrome). Conclusions: Compared to unilateral, bilateral diaphragmatic paralysis may be more challenging to diagnose. On PFT, reduced maximal respiratory pressures, especially the maximal inspiratory pressure, are suggestive. Parsonage-Turner syndrome is rare, usually with unilateral diaphragmatic paralysis, but bilateral cases have been reported.
Dominant‐negative CARD11 loss‐of‐function variant presenting with hypereosinophilic syndrome
Wilson, Bridget E. , Stechelman, Payge Van, Mariani, R , Goswami, Nikita, Sidebottom, Nicole, Bauer, Cindy S. , Mariani, Rachel , Stechelman, Payge Van , Sacco, Keith

Mayo Clinic

Pediatric Allergy and Immunology | November 21, 2023 | Volume: 34 | Issue: 11 | Pages: No page available

10.1111/pai.14041 | PMID 38010008 Get It